timothy sykes logo

Stock News

Annexon Showcases Emerging Treatment with Topline Data on Horizon

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 2/28/2026, 11:24 am ET 2/28/2026, 11:24 am ET | 5 min 5 min read
Annexon Showcases Emerging Treatment with Topline Data on Horizon Thumbnail

Annexon Inc. stocks surged by 7.06% following FDA designation and positive clinical trial milestone announcements.

Healthcare industry expert:

Analyst sentiment – neutral

<> (ANNX) currently presents a concerning market position, characterized by exceedingly negative financial indicators. The company’s return on equity of -61.98% and return on assets of -50.76% reflect severe inefficiencies in generating earnings from resources. Additionally, <>’s pretax profit margin stands at an incredible -34,447.1%, indicating the business is incurring significant losses. Despite a robust current ratio of 4.4, signaling solid short-term liquidity strength, the operating cash flow of -$52,304,000 compounds a precarious financial situation. Based on these key financial metrics, the company is financially beleaguered, yet maintains a potential for turnaround if operational efficiencies improve.

The technical analysis for <>’s stock indicates an upward trend, hinted by the ascending series of weekly closing prices from $4.98 to $5.76. Price patterns denote increasing investor confidence or speculative interest, especially how the price closed at its weekly high of $5.76, often considered a bullish sign. Analyzing the volume trends suggests less emphasis was placed on broad earnings data and more on technical breakouts. Given these patterns, a buy strategy can be considered on dips with a protective stop below $5.27—aligning with the last low—to capture potential price escalation.

Looking at catalysts and future outlook, recent news concerning <>’s vonaprument for geographic atrophy in dry AMD and the accelerated regulatory pathways underscore potential upside if Phase 3 trials show efficacy. The showcased attributes of vonaprument envisage a differentiated approach strongly positioned with robust regulatory backing. However, compared to broader health and biotech benchmarks, <> trails behind, likely due to its fiscal drawbacks. Resistance levels can be anticipated around $6, while support is noted near $5. With encouraging clinical developments but challenging financial underpinnings, prevailing sentiment remains tepid but cautiously optimistic pending upcoming trial results.

Candlestick Chart

Weekly Update Feb 23 – Feb 27, 2026: On Saturday, February 28, 2026 Annexon Inc. stock [NASDAQ: ANNX] is trending up by 7.06%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Annexon Inc. continues to navigate the financial landscape with a focus on forward-looking developments. The recent stock price fluctuations, moving from a February 26 close of $5.27 to $5.76 on February 27, illustrate market responsiveness to increasing anticipation around the company’s endeavors. This positive momentum is reflected in Annexon’s market strategies as it prepares to unveil crucial trial data, which might significantly influence investor perceptions and trading volumes in the near term.

More Breaking News

The financial ratios signal hurdles that Annexon must address; a pre-tax profit margin of -34,447.1 reflects ongoing operational challenges. Meanwhile, a prudent liquidity position, evidenced by a current ratio of 4.4, provides a cushion during these periods of investment in research and development. The balance sheet showcases strategic injections of capital, with a notable $14M from recent stock issuances, potentially fortifying its research initiatives as it prepares for the next strategic phases.

Conclusion

Annexon Inc.’s strategic initiative to host a comprehensive event showcasing vonaprument underscores its commitment to pioneering solutions in ophthalmology while reinforcing its market positioning through engaging key opinion leaders and setting the stage for future growth. With financial maneuvers fostering robust liquidity and capital now directed towards comprehensive trial phases, Annexon may carve out a significant niche in the therapeutic landscape for geographic atrophy in dry AMD. The outlined developments not only signal a potential turning point for the company but also for an innovative approach gaining traction globally. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mantra serves as a reminder for traders that as stakeholders await the 2026 results, market strategies will need to account for both the potential triumphs and challenges inherent in pioneering medical treatments.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”